Posts by Marcela V. Maus, MD, PhD
-
Novel Tandem CAR T-Cell Effective Against Heterogeneous Glioblastoma
Massachusetts General Hospital researchers have developed TanCART, the first chimeric antigen receptor T cell that targets EGFRvIII and IL-13R?2 simultaneously, and found it was effective in vitro and in murine models of heterogeneous glioblastoma, including patient-derived xenografts.
-
Distinct Cellular Dynamics Are Associated With Response to CAR-T Therapy for B-Cell Lymphoma
Marcela V. Maus, MD, PhD, Gad Getz, PhD and colleagues observed that even small increases in CAR regulatory T cells contributed to relapse after axicabtagene ciloleucel treatment of refractory large B-cell lymphoma. This and other findings may optimize the design and individualization of CAR T-cell therapies.
-
Enhanced Interferon Signaling May Improve CAR T-cell Immunotherapy for Solid Tumors
Marcela V. Maus, MD, PhD, Rebecca C. Larson, PhD, and colleagues found that loss of genes in the interferon-gamma receptor signaling pathway is a mechanism of resistance to chimeric antigen receptor (CAR) T-cell therapy, suggesting a way to improve CAR T-cell treatment design for solid tumors.
-
Combination Strategy Potentiates CAR T-cell Therapy for Acute Myeloid Leukemia
Acute myeloid leukemia has been challenging to treat with CAR T-cell therapy. Still, Marcela V. Maus, MD, PhD, Mark B. Leick, MD, and colleagues demonstrated good preclinical results after developing a non-cleavable "hinge" for CD70-targeted T cells and pretreating with azacitidine.
-
Novel Zebrafish Model Allows Assessment of T-Cell–based Immunotherapies at Single-Cell Resolution
David M. Langenau, PhD, Marcela V. Maus, MD, PhD, and colleagues created a new line of transparent zebrafish that allow single-cell imaging of tumor cell killing during immunotherapy with CAR T-cells, bispecific T-cell engagers and antibody–peptide epitope conjugates in a wide range of cancers.
-
CAR T-cell Therapy Feasible for Active Secondary CNS Lymphoma
Central nervous system involvement does not appear to be a risk factor for severe neurotoxicity with CD19-directed CAR T-cell therapy.
-
New Approach to CAR T-Cell Therapy for Glioblastoma Aims to Circumvent Antigen Escape
A dual-antigen approach to immunotherapy for glioblastoma, pioneered at Massachusetts General Hospital, addresses antigenic heterogeneity and may have applications for treating other types of solid tumors.
Biography
Marcela Maus, MD, PhD, is the Director of Cellular Immunotherapy at the Massachusetts General Hospital Cancer Center. Dr. Maus was recently recruited to the Mass General Cancer Center to lead a new program in Cellular Immunotherapy. She is a member of the Center for Cancer Immunology and the Department of Medicine at Mass General, and she is an Associate Professor of Medicine at Harvard Medical School. Her laboratory is generating new forms of chimeric antigen receptors directed to new targets and bringing them to the clinical setting to treat patients with hematologic malignancies and solid tumors.
Dr. Maus trained in internal medicine at U. Penn and at Memorial Sloan Kettering as a hematologist and medical oncologist. Her post-doctoral works was with Michel Sadelain and Carl June, where she focused on pre-clinical development and correlative studies relevant to T cell immunotherapies, designing early-phase trials of T cell therapies for multiple myeloma, chronic lymphocytic leukemia, and glioblastoma.
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.